Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 11/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.47 |
| ▸ | BID | P55957 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9559793 | 0.77 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1BIDBCL2L1MCL1 | |
| SCHEMBL9560072 | 0.76 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1BIDBCL2L1MCL1 | |
| SCHEMBL30273383 | 0.72 | MMP8 (0.51) | SMN1; SMN2 | |
| SCHEMBL9560211 | 0.72 | CYSLTR2 (0.51) | CYSLTR2CYSLTR1BIDBCL2L1MCL1 | |
| SCHEMBL8166768 | 0.72 | TDP1 (0.61) | SMN1; SMN2 | |
| SCHEMBL11207050 | 0.72 | TDP1 (0.61) | SMN1; SMN2 | |
| SCHEMBL11214126 | 0.72 | TDP1 (0.61) | SMN1; SMN2 | |
| SCHEMBL11206749 | 0.72 | TDP1 (0.61) | SMN1; SMN2 | |
| SCHEMBL9428460 | 0.72 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1BIDBCL2L1MCL1 | |
| SCHEMBL9561170 | 0.71 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0358240-B1 | INTERMEDIATES FOR THE PREPARATION OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5034537-A | Alpha-methyl-4-halobenzenemethanamine salts of acids for cardiovascular disorders, respiratory system disorders and antiallergens | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-23 | — | — | US | disclosed |
| US-4939279-A | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0202759-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-20 | — | — | EP | disclosed |
| EP-0358240-A2 | Intermediates for the preparation of leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4874792-A | RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-17 | — | — | US | disclosed |
| US-4820719-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | disclosed |